Understanding GLP-1 Discontinuation Rates
Half of the people who take GLP-1 drugs such as Ozempic quit within the first year. Why?
A Clockwork Ozempic?
A dialogue between Chris Hayes and Nicholas Reville on using GLP1-RA drugs to treat addiction.
The Endocannabinoid System and Addiction
New research looks at developing endocannabinoid receptor agonists for the treatment of obesity, PTSD and drug addiction.
Day One 2025: Accelerating Innovation in Addiction Treatment
The Federation of American Scientists lays out an agenda for accelerating innovation in addiction treatment.
Evaluating Medicaid Section 115 Waivers
A surprising new evaluation of Medicaid section 1115 waivers making it easier to prescribe opioid agonist therapies.